Effect of L-Carnitine on Biomarkers of Myocardial Reperfusion Injury in Patients With STEMI
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorAin Shams University
About this trial
The study aims is to evaluate the efficacy and tolerability of L-Carnitine on biomarkers of myocardial reperfusion injury in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI by the assessment of nitrotyrosine as an oxidative stress marker and Matrix metallopeptidase-2 (MMP-2) as a cardiac fibrosis marker
Eligibility criteria
Qualifiers
Female or male aged >18 and < 75 years.
STEMI patients undergoing PCI.
Disqualifiers
Patients with a recent history of myocardial infarction (MI), a previous PCI, a previous coronary artery bypass graft, or any cardiac surgery.
A late presentation (>12 h), unsuccessful primary PCI (residual stenosis >50% in the culprit lesion after procedure),
Pretreatment with thrombolytic or glycoprotein IIb/IIIa inhibitor therapy before primary PCI,
Concurrent Infectious or active inflammatory disease,
Trial design
Treatments tested in this trial
- L-Carnitine
- The standard care for the management of myocardial infarction post PCI
Treatment groups
76 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov